Top Markets
#1 Cortex Cortex +173.81%
#2 Helium Helium +65.43%
#3 GEKKO GEKKO +49.63%
#4 Pons Pons +21.47%
#5 ADO Protocol ADO Protocol +18.04%
#6 o1.exchange o1.exchange +14.04%
#7 龙虾 (Lobster) 龙虾 (Lobster) +12.45%
#8 Collect on Fanable Collect on Fanable +11.49%
#9 Siren Siren +11.09%
#10 Status Status +11.01%
Coin of the day
Cortex Cortex
Settings
Language
ENGLISH
Currency
USD
Theme
OptiNose, Inc. OptiNose, Inc.

OptiNose, Inc.

OPTN
Rank in Stocks #9145
OptiNose, Inc. is a specialized pharmaceutical company primarily focused on... OptiNose, Inc. is a specialized pharmaceutical company primarily focused on innovating and bringing to market treatments for individuals under the care of ear, nose, throat, and allergy specialists throughout the United States. Its flagship product, XHANCE, utilizes the company's proprietary exhalation delivery system (EDS) to administer a topically-acting corticosteroid. This therapy is approved for treating chronic rhinosinusitis when accompanied by nasal polyps and is currently undergoing Phase IIIb clinical trials for broader chronic sinusitis treatment. The company also offers Onzetra Xsail, a powder-based EDS device, which is commercialized via a licensing agreement with Currax Pharmaceuticals LLC. Further expanding its pipeline, OptiNose is developing OPN-019, an investigational product that integrates a liquid EDS device with an antiseptic agent. Additionally, OptiNose has formed a partnership with Inexia Limited. This collaboration centers on the development, manufacturing, importation, and sale of products containing orexin receptor agonist or positive modulator molecules, intended for the treatment, diagnosis, or prevention of human conditions predominantly linked to orexin receptor activity. Established in 2000, OptiNose, Inc. operates from its corporate headquarters in Yardley, Pennsylvania.
Share Price
$9.60
Last synced: 2025-05-21
Market Cap
$1.08B
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade OptiNose, Inc. (OPTN)

Category

Healthcare
P/S ratio for OptiNose, Inc. (OPTN)
P/S ratio as of August 2026 TTM: 1.24
According to OptiNose, Inc. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.24. At the end of 2023 the company had a P/S ratio of 30.55.
P/S ratio history for OptiNose, Inc. from 2015 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
2026 (TTM) 1.24 42.85%
2024 0.87 -97.16%
2023 30.55 1,366.42%
2022 2.08 -88.74%
2021 18.51 -69.68%
2020 61.04 -63.50%
2019 167.24 -68.05%
2018 523.46 0.00%
2017 0.00 -100.00%
2016 16.31 -99.98%
2015 89.58K 0.00%
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
- -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
- -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
- -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
- -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
7.73 521.93%
IN